CynthiaLGrosskreutzMDPhD
Ophthalmology • Boston, MAAssociate Professor, Ophthalmology, Harvard Medical School
Dr. Grosskreutz is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
243 Charles St
Boston, MA 02114
Education & Training
Massachusetts Eye and Ear Infirmary/Harvard Medical SchoolResidency, Ophthalmology, 1990 - 1993
Steward Carney HospitalInternship, Internal Medicine, 1989 - 1990
University of Iowa Roy J. and Lucille A. Carver College of MedicineClass of 1989
Certifications & Licensure
MA State Medical License 1993 - 2026- American Board of Ophthalmology Ophthalmology
Awards, Honors, & Recognition
- Fellow (FAAO) American Academy of Ophthalmology
Publications & Presentations
PubMed
- 6 citationsComplement factor B is critical for sub-RPE deposit accumulation in a model of Doyne honeycomb retinal dystrophy with features of age-related macular degeneration.Maura A Crowley, Donita L Garland, Holger Sellner, Angela Banks, Lin Fan
Human Molecular Genetics. 2023-01-06 - 101 citationsCalcineurin cleavage is triggered by elevated intraocular pressure, and calcineurin inhibition blocks retinal ganglion cell death in experimental glaucomaWei Huang, John B. Fileta, Adam Dobberfuhl, Theodoros Filippopolous, Yan Guo
Proceedings of the National Academy of Sciences of the United States of America. 2005-08-23 - 158 citationsMechanisms of Retinal Ganglion Cell Injury and Defense in GlaucomaJuan Qu, Danyi Wang, Cynthia L. Grosskreutz
Experimental Eye Research. 2010-07-01
Press Mentions
Novartis : Acquires Arctos Medical, Expanding Optogenetics Portfolio to Bring Gene Therapies to Patients with Severe Vision LossSeptember 23rd, 2021- Gene Therapy, High-Tech Goggles Restore Some Vision to Blind PeopleMay 24th, 2021
- Week in Review: Corneal Shield, Novartis Acquisition, Preloaded IOLNovember 6th, 2020
Grant Support
- Neuroprotection And Retinal Ganglion Cell DeathNational Eye Institute2002–2010
- Hypoxic Regulation Of Vascular Growth In VitroNational Eye Institute1997–1998
- Hypoxic Regulation Of Vascular Growth In VitroNational Eye Institute1994–1996
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
